Navigation Links
CSL Behring Parent Company, CSL Limited, Issues Fourth Corporate Responsibility Report
Date:12/3/2012

water consumption and greenhouse gas emissions per unit of plasma production.

"CSL's reputation as one of the most innovative biopharmaceutical companies in the world and our continued growth are underscored by our commitment to conducting our business responsibly, and actively contributing to the well-being of our communities," said Dr. Brian McNamee, CEO and Managing Director of CSL Limited. "Our Corporate Responsibility Report for 2012 demonstrates this ongoing commitment."

About CSL Limited
Headquartered in Melbourne, Australia, CSL Limited (AUX: CSL) is a global biopharmaceutical company that develops, manufactures and markets biotherapies to prevent and treat rare and serious human diseases. CSL owns major facilities in Australia, Germany, Switzerland and the US, and employs over 11,000 people in more than 25 countries. For more information visit www.csl.com.au.

About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn. For more information visit http://www.cslbehring.com/. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma.

View Our Corporate Responsibility 2012 at http://corporateresponsibility.csl.com.au/.

Contact:
Chris Florentz 
M
'/>"/>

SOURCE CSL Behring
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
2. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
3. CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)
4. Parent Project Muscular Dystrophy Endorses Senate Version of Prescription Drug User Fee Act After Patient Voice Strengthened
5. New Legislation To Make USPSTF More Transparent: Prostate Cancer Roundtable Supports Reform
6. Parents Less Likely To Develop Colds, Carnegie Mellon Research Shows
7. National Call-to-Action to Boost Meningitis Vaccination Rates Supported by Leading Health Organizations, Urges St. Louis Parents to Vaccinate Preteens and Teens
8. National Call-to-Action to Boost Meningitis Vaccination Rates Supported by Leading Health Organizations, Urges Nashville Parents to Vaccinate Preteens and Teens
9. National Call-to-Action to Boost Meningitis Vaccination Rates Supported by Leading Health Organizations, Urges Minneapolis-St. Paul Parents to Vaccinate Preteens and Teens
10. TUV Rheinland Confirms Apparent Fraud in Mislabeling of DRX Products Manufactured by HTRD and Excite Medical
11. Webcams Help Parents Keep Watch Over Their Babies During Hurricane Isaac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... LAWRENCE, Mass. , Aug. 1, 2014  NxStage Medical, ... innovative dialysis products, today announced that Jeffrey H. Burbank ... Financial Officer, will present at the 34 th Annual ... Boston, MA , on Wednesday, August 13 ... event will be made available at http://ir.nxstage.com/ .  ...
(Date:8/1/2014)... JUPITER, Fla. , Aug. 1, 2014 ... company whose patented and proprietary technologies are used to ... the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, ... for the second quarter ended June 30, 2014 after ... host a conference call that day at 5:00 p.m. ...
(Date:7/31/2014)... , July 31, 2014  According to data ... Services, the 2015 average monthly Medicare Part D premium ... far lower than was originally projected, the Pharmaceutical Care ... D program continues to be a bright spot in ... choices in each region and using cutting edge, cost-saving ...
Breaking Medicine Technology:NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3
... GeneXpert(R) System ... ... today announced the U.S. Food & Drug Administration (FDA) categorized,Cepheid,s ... Clinical Laboratory Improvement Amendments (CLIA).,The new test is designed for ...
... Michael J. Fox,Foundation today announced the availability of ... toward transformative treatments and a cure for,Parkinson,s disease., ... researchers through the,Foundation,s Pipeline Programs, five separate initiatives ... drug development pipeline. This includes,early-stage discovery research, translational ...
Cached Medicine Technology:Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA 2Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA 3Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA 4Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinson's Disease Research 2Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinson's Disease Research 3Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinson's Disease Research 4
(Date:8/1/2014)... This week marks a significant milestone ... week of paying commissions to its independent distributor sales ... January 2005 total $1,405,954,677.06. , MonaVie distributors can be ... pays commissions in 18 different currencies, including: AUD, EUR, ... PLN, USD, SGD, KRW, TWD, THB and GBP. ...
(Date:8/1/2014)... A leading dress supplier, Discount-Dress.com, explores a variety of ... any lady’s wardrobe fashionable and exciting. Recently, the company has ... To attract more people, it is now launching a special ... to 65% off. , “Summer is the season of short ... to our collection of ‘ 2014 summer short styles .’ ...
(Date:8/1/2014)... August 01, 2014 Transparency Market ... the addition of a comprehensive report on the ... System Market (Large Volume, Disposable, Syringe, Ambulatory and ... Trends And Forecast, 2013 – 2019’ is now ... http://www.transparencymarketresearch.com . , To begin with, the report ...
(Date:8/1/2014)... CentraComm, a leading managed IT security ... the Pure Storage® Authorized Reseller program. , ... experience designed to meet the rigorous resiliency, scalability, ... diverse markets, and for a variety of high ... years. , The Pure Storage FlashArray was ...
(Date:8/1/2014)... HealthDay Reporter THURSDAY, July 31, 2014 ... Africa has a well-earned reputation as one of the world,s ... intense medical care can greatly improve a person,s chances of ... wreaks life-threatening havoc within the body by attacking multiple organ ... back on the basics of "good meticulous intensive care," supporting ...
Breaking Medicine News(10 mins):Health News:MonaVie Records 500th Commission Week, Having Paid Out More Than $1.4B in Distributor Commissions 2Health News:Discount-Dress.com’s Top Trend Report: 2014 Summer Short Bridesmaid Dresses Now for Sale 2Health News:Transparency Market Research Adds Report on Global Infusion System Market to its Repository 2Health News:Transparency Market Research Adds Report on Global Infusion System Market to its Repository 3Health News:CentraComm Accepts Pure Storage Authorized Reseller Partner Invitation 2Health News:CentraComm Accepts Pure Storage Authorized Reseller Partner Invitation 3Health News:There's No Ebola Cure, But Early Intensive Treatment Boosts Survival 2Health News:There's No Ebola Cure, But Early Intensive Treatment Boosts Survival 3
... Lifeclinic International is this year,s Gold Sponsor of the Harvard Business ... Joseph B. Martin Conference Center, Harvard Medical School, November 6 - ... ... 2008 -- Lifeclinic International, Inc. , the world,s leading manufacturer ...
... Jazz,Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced today ... On Tuesday, November 11, 2008 at 2:50 p.m. ... a corporate presentation at the,Rodman & Renshaw 10th Annual ... November 12, 2008 at 3:30 p.m. MST (5:30 p.m. ...
... Product Will Be Sold by A Uniquely-Trained Sales ... ... Group plc,(LSE: PSK) today announced that SANCUSO(R) (Granisetron Transdermal System),is now available ... States. Sancuso was approved by,the U.S. Food and Drug Administration (F.D.A.) in ...
... have vaccination rates far below goals, study finds , , ... adolescents with asthma and other high-risk illnesses are getting ... vaccination rates from 1992 to 2002 for 18,703 adolescents ... conditions. , During the study period, vaccination rates improved, ...
... Fifteen Abstracts Will Be Featured at ASN, ... a leading,provider of kidney care services for those ... DaVita Clinical Research(R) (DCR),recently contributed fifteen abstracts to ... American Society of Nephrology. These,abstracts were developed both ...
... Nov. 4 The Quantum Group,Inc. (Amex: ... today that Noel J. Guillama, President & Chief ... Annual Westergaard,Conference on November 12, 2008. Mr. Guillama ... and Chief Technology & Innovations Officer,and Ron Smith, ...
Cached Medicine News:Health News:Lifeclinic International Lead Sponsor at Harvard Business School Health Conference 2Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 2Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 3Health News:Too Many High-Risk Teens Not Getting Flu Shots 2Health News:DaVita Abstracts Accepted into American Society of Nephrology Meeting 2Health News:DaVita Abstracts Accepted into American Society of Nephrology Meeting 3Health News:DaVita Abstracts Accepted into American Society of Nephrology Meeting 4Health News:The Quantum Group Inc. To Present at Paulson Investment's 31st Annual Westergaard Conference 2Health News:The Quantum Group Inc. To Present at Paulson Investment's 31st Annual Westergaard Conference 3
Ballard trach care HMES and filters, tv 1500, HME with built-in flex tube...
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours...
... The Portex® Thermovent® T helps provide protection to ... is small and extremely lightweight making it ideal ... With a high rate of heat and moisture ... retention., ,All HMEs and filters have ISO ...
... helps provide protection to the exposed airway of ... lightweight making it ideal for active young children ... of heat and moisture recovery, it ensures patient ... and filters have ISO standard tapered ends to ...
Medicine Products: